Longeveron LGVN
NASDAQ LGVN
$0.84 +0.02 (+2.02%)
At close: Aug 21, 2026 · 4:00 PM EDT

Longeveron (LGVN) Cash from Financing Activities (2020 - 2026)

Longeveron (LGVN) posted quarterly Cash from Financing Activities of $15.5 million for Q1 2026, up 26801.72% year-over-year from N/an in Q1 2025, and up 1893.18% quarter-over-quarter from $777000.0 in Q4 2025.

Longeveron (LGVN) Cash from Financing Activities (2020 - 2026) Analysis & Trends

Longeveron's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $15.5 million for Q1 2026.

  • In Q1 2026, Cash from Financing Activities rose 26801.72% year-over-year to $15.5 million; the TTM figure through Mar 2026 stood at $20.2 million (down 29.49% YoY), while the FY2025 annual figure was $4.7 million, down 83.78% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at $15.5 million, up from $777000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $15.5 million in Q1 2026, with the low at -$193000.0 in Q4 2022.
  • The 5-year median for Cash from Financing Activities is -$27000.0 (2022), against an average of $3.2 million.
  • The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities plunged 678.95% in 2022, then surged 27548.0% in 2024.
  • Longeveron's Cash from Financing Activities stood at -$193000.0 in 2022, then surged by 2905.7% to $5.4 million in 2023, then tumbled by 100.92% to -$50000.0 in 2024, then jumped by 1654.0% to $777000.0 in 2025, then surged by 1893.18% to $15.5 million in 2026.
  • Business Quant data shows LGVN's Cash from Financing Activities at $15.5 million in Q1 2026, $777000.0 in Q4 2025, and $4.1 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 14.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -6.05 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 36.24 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -16.65 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 27.18 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -273.15 Mn
10 Longeveron 26.51 Mn 16.41 Mn 182,000.00 75,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 75,000.00
Jun 30, 2026 75,000.00
Mar 31, 2026 15.49 Mn
Mar 31, 2026 15.49 Mn
Dec 31, 2025 777,000.00
Dec 31, 2025 777,000.00
Sep 30, 2025 4.08 Mn
Sep 30, 2025 4.08 Mn
Jun 30, 2025 -133,000.00
Jun 30, 2025 -133,000.00
Mar 31, 2025 -58,000.00
Mar 31, 2025 -58,000.00
Dec 31, 2024 -50,000.00
Dec 31, 2024 -50,000.00
Sep 30, 2024 13.72 Mn
Sep 30, 2024 13.72 Mn
Jun 30, 2024 15.05 Mn
Jun 30, 2024 15.05 Mn
Mar 31, 2024 63,000.00
Mar 31, 2024 63,000.00